835
Views
18
CrossRef citations to date
0
Altmetric
Short Report

Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy

, , &
Pages 75-79 | Received 02 Mar 2016, Accepted 05 Sep 2016, Published online: 27 Sep 2016

References

  • American Psychiatric Association (APA). 2000. Diagnostic and statistical manual of mental disorders, fourth edition, Text Revision. Washington, DC: American Psychiatric Association.
  • American Psychiatric Association (APA). 2001. Practice guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry. 158:1–52.
  • Baker-Glenn E, Steels M, Evans C. 2010. Use of psychotropic medication among psychiatric out-patients with personality disorders. Psychiatrist. 34:83–86.
  • Bellino S, Bozzatello P, Rocca G, Bogetto F. 2014. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol (Oxford). 28:125–132.
  • Bellino S, Rinaldi C, Bozzatello P, Bogetto F. 2011. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose. Curr Med Chem. 18:322–3329.
  • Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W. 2015. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 25:63–772.
  • First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS. 1997. User’s guide for the structured clinical interview for DSM-IV Axis II personality disorders (SCID-II). Washington, DC: American Psychiatric Press.
  • Haw C, Stubbs J. 2011. Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract. 15:280–285.
  • Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Moller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Personality Disorders. 2007. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 8:212–244.
  • Ingenhoven TJ, Duivenvoorden HJ. 2011. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 31:489–496.
  • Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. 2010. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 71:14–25.
  • Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. 2010. Pharmacotherapy for borderline personality disorder: cochrane systematic review of randomised trials. Br J Psychiatry. 196:4–12.
  • Links PS, Boggild A, Sarin N. 2001. Psychopharmacology of personality disorders: review and emerging issues. Curr Psychiatry Rep. 3:70–76.
  • National Health and Medical Research Council. 2012. Clinical practice guideline for the management of borderline personality disorder. Melbourne: National Health and Medical Research Council.
  • National Institute for Clinical Excellence (NICE). 2008. Borderline personality disorder: treatment and management. London, England: National Institute for Health and Clinical Excellence.
  • Paris J. 2004. Is hospitalization useful for suicidal patients with borderline personality disorder? J Pers Disord. 18:240–247.
  • Pascual JC, Blanco AM, Soler J, Ferrer A, Tiana T, Alvarez E, Pérez V. 2010. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol. 25:349–355.
  • Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. 2015. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 76:e512–e518.
  • Percudani M, Belloni G, Contini A, Barbui C. 2001. Monitoring community psychiatric services in Italy: differences between patients who leave care and those who stay in treatment. Br J Psychiatry. 180:254–259.
  • Stoffers JM, Lieb K. 2015. Pharmacotherapy for borderline personality disorder-current evidence and recent trends. Curr Psychiatry Rep. 17:534. doi: 10.1007/s11920-014-0534-0.
  • Stoffers J, Voellm BA, Ruecker G, Timmer A, Huband N, Lieb K. 2010. Pharmacological interventions for borderline personality disorder. Cochrane Database of Syst Rev. 16:CD005653.
  • Taylor D, Paton C, Kapur S. 2013. The Maudsley prescribing guidelines in psychiatry. 11th ed. Oxford, UK: Wiley-Blackwell.
  • Vita A, De Peri L, Sacchetti E. 2011. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials. J Clin Psychopharmacol. 31:813–824.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.